Literature DB >> 19845691

Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1.

A M Nyström1, S Ekvall, J Allanson, C Edeby, M Elinder, G Holmström, M L Bondeson, G Annerén.   

Abstract

Noonan syndrome (NS) and neurofibromatosis type I (NF1) belong to a group of clinically related disorders that share a common pathogenesis, dysregulation of the RAS-MAPK pathway. NS is characterized by short stature, heart defect, pectus deformity and facial dysmorphism, whereas skin manifestations, skeletal defects, Lisch nodules and neurofibromas are characteristic of NF1. Both disorders display considerable clinical variability. Features of NS have been observed in individuals with NF1 -a condition known as neurofibromatosis-Noonan syndrome (NFNS). The major gene causing NFNS is NF1. Rarely, a mutation in PTPN11 in addition to an NF1 mutation is present. We present the clinical and molecular characterization of a family displaying features of both NS and NF1, with complete absence of neurofibromas. To investigate the etiology of the phenotype, mutational analysis of NF1 was conducted, revealing a novel missense mutation in exon 24, p.L1390F, affecting the GAP-domain. Additional RAS-MAPK pathway genes were examined, but no additional mutations were identified. We confirm that NF1 mutations are involved in the etiology of NFNS. Furthermore, based on our results and previous studies we suggest that evaluation of the GAP-domain of NF1 should be prioritized in NFNS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19845691     DOI: 10.1111/j.1399-0004.2009.01233.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  14 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  NF1 exon 22 analysis of individuals with the clinical diagnosis of neurofibromatosis type 1.

Authors:  Talia M Muram-Zborovski; Cecily P Vaughn; David H Viskochil; Heather Hanson; Rong Mao; David A Stevenson
Journal:  Am J Med Genet A       Date:  2010-08       Impact factor: 2.802

Review 3.  Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Ann N Y Acad Sci       Date:  2010-10-19       Impact factor: 5.691

Review 4.  Noonan syndrome and clinically related disorders.

Authors:  Marco Tartaglia; Bruce D Gelb; Martin Zenker
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-02       Impact factor: 4.690

Review 5.  LZTR1 molecular genetic overlap with clinical implications for Noonan syndrome and schwannomatosis.

Authors:  Kirsten M Farncombe; Emily Thain; Carolina Barnett-Tapia; Hamid Sadeghian; Raymond H Kim
Journal:  BMC Med Genomics       Date:  2022-07-15       Impact factor: 3.622

6.  A new nonsense mutation in the NF1 gene with neurofibromatosis-Noonan syndrome phenotype.

Authors:  Sevgi Yimenicioğlu; Ayten Yakut; Kadri Karaer; Martin Zenker; Arzu Ekici; Kürşat Bora Carman
Journal:  Childs Nerv Syst       Date:  2012-09-11       Impact factor: 1.475

7.  Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.

Authors:  Shay Ben-Shachar; Shlomi Constantini; Hen Hallevi; Emma K Sach; Meena Upadhyaya; Gareth D Evans; Susan M Huson
Journal:  Eur J Hum Genet       Date:  2012-10-10       Impact factor: 4.246

8.  Growth Hormone Deficiency in a Child with Neurofibromatosis-Noonan Syndrome.

Authors:  Doğuş Vurallı; Nazlı Gönç; Dominique Vidaud; Alev Özön; Ayfer Alikaşifoğlu; Nurgün Kandemir
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-12-18

9.  Neurofibromatosis Type 1 Associated with Hashimoto's Thyroiditis: Coincidence or Possible Link.

Authors:  Junaid Nabi
Journal:  Case Rep Neurol Med       Date:  2013-04-18

Review 10.  Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms.

Authors:  Jody F Longo; Shannon M Weber; Brittany P Turner-Ivey; Steven L Carroll
Journal:  Adv Anat Pathol       Date:  2018-09       Impact factor: 4.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.